3-[3,5-dichloro salicylamido] rhodanine was obtained by method dithiocarbamat. Condensation of 3-[3,5-dichloro salicylamido] rhodanine with p-dimethylaminobenzaldehyd, benzaldehyd, furfural, aldehyd salicylic to get four 5 -aryliden 3-[3,5-dichloro salicylamido] rhodanine. Condensation 3-[3,5-dichloro salicylamido] rhodanine with phenylhydrazin to get 2-phenyl hydrazon 3-[3,5-dichloro salicylamido] rhodanine. All of them were not seen in reference document. The structures of the obtained products were characterized by elemental analysis and IR spectroscopy. The results obtained on the test of antibiotic and antifungal activities showed that most of them had strong effect on tested bacteria Gram(+) and weak effect on bacteria Gram (-) and fungus.
Rhodanine ; Analogs & derivatives

OBJECTIVETo synthesize epalrestat and to improve the method of synthesis.

METHODSGlycine reacted with carbondisulfide,then with ClCH(2)COONa to give 3-carboxymethylrhodanine. PhCHO reacted with CH(3)CH(2)CHO in NaOH/EtOH solution to produce 2-methylcinnamaldehyde.3-carboxymethylrhodanine and 2-methylcinnamaldehyde were treated with NH(3).H(2)O to obtain epalrestat.

RESULTThe described method was effective in synthesis of Epalrestat and the yield was higher than that of in references.

CONCLUSIONThe results suggest that this method is suitable for industrial production.

Aldehyde Reductase ; antagonists & inhibitors ; Enzyme Inhibitors ; chemical synthesis ; Rhodanine ; analogs & derivatives ; chemical synthesis ; Thiazolidines

To discover novel antitumor rhodanine unsaturated ketones, a series of fluoroquinolone (rhodanine α, β-unsaturated ketone) amine derivatives (5a-5r) were designed and synthesized with fluoroquinolone amide scaffold as a carrier. The structures of eighteen title compounds were characterized by elemental analysis, 1H NMR and MS. The in vitro anti-proliferative activity against Hep-3B, Capan-1 and HL60 cells was evaluated by MTT assay. The results showed that the title compounds not only had more significant anti-proliferative activity against three tested cancer cell lines than that of the parent ciprofloxacin 1, but also exhibited the highest activity against Capan-1 cells. The SAR revealed that some compounds carrying aromatic heterocyclic rings or phenyl attached to an electron-withdrawing carboxyl or sulfonamide substituent were comparable to or better than comparison doxorubicin against Capan-1 cells. As such, it suggests that fluoroquinolone (rhodanine α, β-unsaturated ketone) amines are promising leads for the development of novel antitumor fluoroquinolones or rhodanine analogues.
Amides ; chemical synthesis ; pharmacology ; Antineoplastic Agents ; chemical synthesis ; pharmacology ; Cell Line, Tumor ; Fluoroquinolones ; chemical synthesis ; pharmacology ; HL-60 Cells ; Humans ; Ketones ; chemical synthesis ; pharmacology ; Rhodanine ; chemical synthesis ; pharmacology

OBJECTIVE: To observe the protective effects of epalrestat (EPS) on interstitial fibrosis in unilateral ureteral obstruction (UUO) rats and its mechanism. METHODS: Rats were randomly divided into four groups: sham group, UUO group, UUO + epalrestat (50 or 100 mg/kg), 8 rats in each group.Rats in UUO and UUO + epalrestat group were obstructed left ureter.In the sham group, rats had their left ureters exposed and manipulated without ligation.Animals for epalrestat treatment received daily drug via gavage for 3 weeks, the rats of sham and UUO groups received equal amount of sodium carboxymethyl cellulose with the same regimen.Renal tissues pathological changes and collagen deposition were observed by HE and Masson's staining.The aldose reductase(AR) expression in renal tissues was measured by immunohistochemisty.The expression levels of collagen I, collagen III, alpha-smooth muscle actin (α-SMA), fibroblast-specific protein1 (FSP-1), fibronectin (FN), epithelial cadherin (E-cadherin), transforming growth factor-β1 (TGF-β1) and AR from kidney tissues were measured by real-time RT-PCR or Western blot. RESULTS: Compared with the sham group, the renal tissues of the UUO group showed significant fibrosis, including renal tubular epithelial cell atrophy and vacuolated degeneration, collagen deposition, fibroblasts and myofibroblasts proliferation and inflammatory cell infiltration, and concomitantly with the expressions of collagen I, collagen III, TGF-β1, AR, α-SMA, FSP-1 and FN were remarkably up-regulated, but E-cadherin was significantly reduced in UUO group.Compared with the UUO group, after 3 weeks epalrestat administration, the level of renal interstitial fibrosis was obviously ameliorated and the expressions of collagen I, collagen III, TGF-β1, AR, α-SMA, FSP-1 and FN were remarkably down-regulated, but E-cadherin was significantly increased in rats of epalrestat groups. CONCLUSION These results suggest that epalrestat attenuates renal interstitial fibrosis possibly through inhibition of EMT via inhibiting TGF-β1 and AR expression.
Animals ; Enzyme Inhibitors ; pharmacology ; Fibrosis ; complications ; drug therapy ; Random Allocation ; Rats ; Rats, Sprague-Dawley ; Rhodanine ; analogs & derivatives ; pharmacology ; Thiazolidines ; pharmacology ; Ureteral Obstruction ; complications ; drug therapy

Aldose reductase is a member of aldehyde-keto reductase superfamily widely existing in the kidney, adrenal gland, lens, retina, nerve, heart, placenta, brain, skeletal muscle, testis, blood vessels, lung, liver, et al. It is a reduced nicotinamide-adenine dinucleotide phosphate (NADPH)-dependent enzyme catalyzing the reduction of various aldehydes and ketones to the corresponding alcohol. It is involved in many oxidative stress diseases, cell signal transduction and cell proliferation process as well as diabetes complications. In recent years, some progress has been made in research of the activity and gene regulation of aldose reductase and the relation with many common diseases.
Aldehyde Reductase ; antagonists & inhibitors ; metabolism ; physiology ; Animals ; Cell Proliferation ; Diabetes Complications ; drug therapy ; enzymology ; Enzyme Inhibitors ; therapeutic use ; Humans ; Oxidative Stress ; Rhodanine ; analogs & derivatives ; therapeutic use ; Signal Transduction ; Thiazolidines ; therapeutic use

OBJECTIVETo study the protective effect of epalrestat against endothelial cell injuries induced by high glucose.

METHODSHuman umbilical vein endothelial cells were pretreated with epalrestat (0.1 µmol/L) for 30 min followed by exposure to high glucose for 8 h. NO concentration in the cell culture supernatant was assayed using chemiluminescence method following the exposure. Real-time PCR and Western blotting were used to detect eNOS mRNA and protein expression levels and the protein expressions of AR gene (the target gene of epalrestat) and NOX4 (the upstream gene of NO).

RESULTSCompared with mannitol treatment, an 8-h exposure to high glucose caused significantly decreased NO levels and eNOS mRNA and protein expression in the vascular endothelial cells (P<0.05). Pretreatment with epalrestat prior to high glucose exposure resulted in elevated eNOS mRNA and protein expression levels and NO up-regulation in the cell culture as compared with the glucose exposure alone group (P<0.05), causing also decreased expression of AR and NOX4 in the cells.

CONCLUSIONSHigh glucose can induce endothelial cell damage characterized by a lowered level of NO secretion. Epalrestat can protect the endothelial cells against high glucose-induced injury by inhibiting the expression of AR and NOX4.

Aldehyde Reductase ; antagonists & inhibitors ; Cells, Cultured ; Endothelium, Vascular ; drug effects ; metabolism ; Enzyme Inhibitors ; pharmacology ; Glucose ; adverse effects ; Human Umbilical Vein Endothelial Cells ; cytology ; drug effects ; Humans ; NADPH Oxidase 4 ; NADPH Oxidases ; metabolism ; Nitric Oxide Synthase Type III ; metabolism ; RNA, Messenger ; genetics ; Rhodanine ; analogs & derivatives ; pharmacology ; Thiazolidines ; pharmacology

Epalrestat is the unique aldose reductase inhibitor on the market, which was mainly used for the diabetic neuropathy. Lenses osmotic expansion could be induced by galactose to mimic the pathological process of diabetic cataract in vitro. In present study, we mainly investigated whether epalrestat possesses inhibitory effect on the lens osmotic expansion. The results indicated that epalrestat could not only markedly inhibit rat lens osmotic expansion in vitro, but also significantly reduced the high expression of the osmotic expansion-related genes such as AR and AQP1 in mRNA and protein levels. The findings may provide an important reference to epalrestat in the clinical application for the treatment of diabetic cataract.
Aldehyde Reductase ; antagonists & inhibitors ; biosynthesis ; genetics ; Animals ; Aquaporin 1 ; genetics ; metabolism ; Cataract ; etiology ; metabolism ; pathology ; Diabetes Mellitus, Experimental ; complications ; Enzyme Inhibitors ; pharmacology ; Galactose ; antagonists & inhibitors ; Lens, Crystalline ; drug effects ; metabolism ; pathology ; Male ; Osmosis ; drug effects ; RNA, Messenger ; metabolism ; Rats ; Rats, Sprague-Dawley ; Rhodanine ; analogs & derivatives ; pharmacology ; Thiazolidines ; pharmacology